Physician profile
David Bradlee
NPI 1790731693
$3,266.18
in general payments reported to CMS, 2019-2025
35 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $530 · 2021: $403 · 2022: $465 · 2023: $563 · 2024: $327 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.35 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $510.33 | 2020-2025 | Korlym |
| Medtronic, INC. | $421.82 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Guardian Sensor (3) |
| Novo Nordisk INC | $375.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amneal Pharmaceuticals LLC | $225.01 | 2019-2025 | Unithroid |
| Lilly USA, LLC | $216.04 | 2019-2025 | Jardiance, Mounjaro |
| Abbott Laboratories | $200.85 | 2019-2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $167.63 | 2019-2022 | |
| Abbvie INC. | $155.95 | 2019-2024 | Synthroid |
| Sanofi-Aventis U.S. LLC | $128.43 | 2019-2025 | |
| Mannkind Corporation | $89.16 | 2019-2022 | |
| Amryt Pharma Holdings LTD | $84.42 | 2022-2023 | Mycapssa |
| Amgen INC. | $78.86 | 2019-2025 | Evenity, Tepezza, Prolia |
| Ibsa Pharma INC. | $76.00 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $70.59 | 2020-2024 | Recorlev |
| Dexcom, INC. | $49.62 | 2020-2023 | Dexcom G6 Transmitter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $49.44 | 2022-2025 | Teriparatide |
| Janssen Pharmaceuticals, INC | $40.53 | 2019-2020 | |
| Cequr Corporation | $32.68 | 2021-2023 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $25.94 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $23.92 | 2019 | |
| Madrigal Pharmaceuticals | $22.66 | 2025 | Rezdiffra |
| Recordati_rare_diseases_inc. | $22.04 | 2025 | Isturisa |
| Ascendis Pharma Endocrinology INC | $20.67 | 2023 | |
| Beta Bionics, INC. | $17.85 | 2023 | Ilet Bionic Pancreas |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.31 | 2021 | |
| Radius Health, INC. | $17.21 | 2023 | Tymlos |
| Amphastar Pharmaceuticals, INC. | $16.01 | 2024 | |
| Azurity Pharmaceuticals, INC. | $15.37 | 2025 | Azmiro |
| Pfizer INC. | $13.96 | 2023 | |
| Horizon Therapeutics Plc | $13.91 | 2022 | |
| Insulet Corporation | $12.97 | 2019 | |
| Senseonics, Incorporated | $12.00 | 2020 | |
| Becton, Dickinson and Company | $11.97 | 2019 | |
| Lifescan, INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bradlee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.